| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1044851488 |
| P356 | DOI | 10.1007/S00210-004-0951-4 |
| P698 | PubMed publication ID | 15322733 |
| P2093 | author name string | Anil Misra | |
| Antony R Knight | |||
| Guy Kennett | |||
| Karen Benwell | |||
| Kathleen Quirk | |||
| Dean Revell | |||
| Mike Bickerdike | |||
| P2860 | cites work | The pharmacology and distribution of human 5‐hydroxytryptamine2B (5‐HT2b) receptor gene products: comparison with 5‐HT2a and 5‐HT2c receptors | Q24312997 |
| 5-HT(2B) receptors play a key role in mediating the excitatory effects of 5-HT in human colon in vitro | Q24673230 | ||
| Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells | Q24675490 | ||
| Further characterization of 5-hydroxytryptamine receptors (putative 5-HT2B) in rat stomach fundus longitudinal muscle | Q24679434 | ||
| In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties | Q24679694 | ||
| A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding | Q25938984 | ||
| Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction | Q27860958 | ||
| Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications | Q28139347 | ||
| A review of central 5-HT receptors and their function | Q28142963 | ||
| Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension | Q28203160 | ||
| 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro | Q28205864 | ||
| International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin) | Q28239487 | ||
| Molecular cloning, functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine2B receptor | Q28247641 | ||
| Agonist activity of LSD and lisuride at cloned 5HT 2A and 5HT 2C receptors | Q28271754 | ||
| Pharmacologic characterization of the human 5-hydroxytryptamine2B receptor: evidence for species differences | Q28279082 | ||
| Evidence that hypophagia induced by mCPP and TFMPP requires 5-HT1C and 5-HT1B receptors; hypophagia induced by RU 24969 only requires 5-HT1B receptors | Q28284027 | ||
| 5-HT2 receptor subtypes: a family re-united? | Q28303964 | ||
| High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action | Q28374171 | ||
| Evidence for expression of the 5-hydroxytryptamine-2B receptor protein in the rat central nervous system | Q28583455 | ||
| Pharmacological characterisation of human 5-HT2 receptor subtypes | Q32077960 | ||
| Effects of selected serotonin 5-HT(1) and 5-HT(2) receptor agonists on feeding behavior: possible mechanisms of action | Q33899072 | ||
| Behavioral effects of AMI-193, a 5-HT(2A)- and dopamine D(2)-receptor antagonist, in the squirrel monkey | Q33928730 | ||
| Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis | Q34041519 | ||
| Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors | Q34086043 | ||
| Ketanserin and spiperone as templates for novel serotonin 5-HT(2A) antagonists | Q34132180 | ||
| Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens | Q34167036 | ||
| Neuroendocrine evidence that (S)-2-(chloro-5-fluoro-indol- l-yl)-1-methylethylamine fumarate (Ro 60-0175) is not a selective 5-hydroxytryptamine(2C) receptor agonist. | Q34179708 | ||
| BW 723C86, a 5-HT2B receptor agonist, causes hyperphagia and reduced grooming in rats | Q34425588 | ||
| SB 242084, a Selective and Brain Penetrant 5-HT 2C Receptor Antagonist | Q34432766 | ||
| 3HRauwolscine: an antagonist radioligand for the cloned human 5-hydroxytryptamine2B (5-HT2B) receptor | Q34455622 | ||
| 5-HT2C receptor agonists as potential drugs for the treatment of obesity | Q35100828 | ||
| Multiple serotonin receptors: clinical and experimental aspects | Q40558564 | ||
| Receptors for 5-hydroxytryptamine: current perspectives on classification and nomenclature | Q40645621 | ||
| A proposed new nomenclature for 5-HT receptors. | Q40846227 | ||
| Immunohistochemical localisation of the 5-HT2C receptor protein in the rat CNS. | Q40901462 | ||
| Multiple serotonin receptors: opportunities for new treatments for obesity? | Q41026153 | ||
| Differential radioligand binding properties of [3H]5-hydroxytryptamine and [3H]mesulergine in a clonal 5-hydroxytryptamine1C cell line | Q41614473 | ||
| Effects of antidepressants on intracellular Ca2+ mobilization in CHO cells transfected with the human 5-HT2C receptors | Q42522352 | ||
| Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors | Q42536303 | ||
| Radiolabelling of the human 5-HT2A receptor with an agonist, a partial agonist and an antagonist: effects on apparent agonist affinities | Q42557857 | ||
| Novel Agonists of 5HT2C Receptors. Synthesis and Biological Evaluation of Substituted 2-(Indol-1-yl)-1-methylethylamines and 2-(Indeno[1,2-b]pyrrol-1-yl)-1-methylethylamines. Improved Therapeutics for Obsessive Compulsive Disorder | Q42797658 | ||
| Molecular pharmacological differences in the interaction of serotonin with 5-hydroxytryptamine1C and 5-hydroxytryptamine2 receptors | Q42817692 | ||
| Characterisation of agonist binding on human 5-HT2C receptor isoforms | Q43653871 | ||
| Multiple conformations of native and recombinant human 5-hydroxytryptamine(2a) receptors are labeled by agonists and discriminated by antagonists. | Q43741377 | ||
| Indoline derivatives as 5-HT(2C) receptor agonists. | Q44841742 | ||
| Antagonism of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane stimulus with a newly identified 5-HT2- versus 5-HT1C-selective antagonist | Q45092262 | ||
| Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol | Q45152577 | ||
| Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors | Q48149092 | ||
| LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex. | Q48933896 | ||
| Effect of SB 200646A, a 5-HT2C/5-HT2B receptor antagonist, in two conflict models of anxiety | Q51126109 | ||
| Reduced satiating effect of d -fenfluramine in serotonin 5-HT 2C receptor mutant mice | Q60054745 | ||
| Effect of 1-(m-chlorophenyl)piperazine and 1-(m-trifluoromethylphenyl)piperazine on locomotor activity. | Q64895801 | ||
| (+)-cis-4,5,7a,8,9,10,11,11a-octahydro-7H-10-methylindolo[1,7- bc][2,6]-naphthyridine: a 5-HT2C/2B receptor antagonist with low 5-HT2A receptor affinity | Q72472351 | ||
| Model studies on a synthetically facile series of N-substituted phenyl-N'-pyridin-3-yl ureas leading to 1-(3-pyridylcarbamoyl) indolines that are potent and selective 5-HT(2C/2B) receptor antagonists | Q73409135 | ||
| Mechanism of the thermogenic effect of Metabolite 2 (BTS 54 505), a major pharmacologically active metabolite of the novel anti-obesity drug, sibutramine | Q74629242 | ||
| 5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function | Q77425309 | ||
| P433 | issue | 2 | |
| P921 | main subject | pharmacology | Q128406 |
| P304 | page(s) | 114-123 | |
| P577 | publication date | 2004-07-30 | |
| P1433 | published in | Naunyn-Schmiedeberg's Archives of Pharmacology | Q1468251 |
| P1476 | title | Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors | |
| P478 | volume | 370 |
| Q37359930 | (1R, 3S)-(-)-trans-PAT: a novel full-efficacy serotonin 5-HT2C receptor agonist with 5-HT2A and 5-HT2B receptor inverse agonist/antagonist activity |
| Q48007275 | 5-HT1A and 5-HT2A receptor control of a panic-like defensive response in the rat dorsomedial hypothalamic nucleus |
| Q38037141 | 5-HT2 ligands in the treatment of anxiety and depression |
| Q48183061 | 5-HT2A receptor activation of the external urethral sphincter and 5-HT2C receptor inhibition of micturition: A study based on pharmacokinetics in the anaesthetized female rat |
| Q34766538 | 5-HT2C ligands: recent progress |
| Q50667437 | 5-HT2C receptor regulation of defensive responses in the rat dorsal periaqueductal gray |
| Q37298797 | 5-HT2C-like receptors in the brain of Xenopus laevis initiate sex-typical fictive vocalizations |
| Q37730936 | 5-Hydroxy-2-(2-phenylethyl)chromone (5-HPEC): a novel non-nitrogenous ligand for 5-HT2B receptor. |
| Q42155969 | 5HT2Aand5HT2BReceptors Contribute to Serotonin-Induced Vascular Dysfunction in Diabetes |
| Q64892254 | A Hallucinogenic Serotonin-2A Receptor Agonist Reduces Visual Response Gain and Alters Temporal Dynamics in Mouse V1. |
| Q42839466 | A pronociceptive role for the 5-HT2 receptor on spinal nociceptive transmission: An in vivo electrophysiological study in the rat |
| Q34176654 | Abuse liability profile of three substituted tryptamines. |
| Q48586285 | Activation of serotonin 5-HT2A receptors inhibits high compulsive drinking on schedule-induced polydipsia. |
| Q46619353 | Alprazolam potentiates the antiaversive effect induced by the activation of 5-HT(1A) and 5-HT (2A) receptors in the rat dorsal periaqueductal gray |
| Q31114482 | Application of palladium-mediated (18)F-fluorination to PET radiotracer development: overcoming hurdles to translation |
| Q50919178 | Attenuated PLD1 association and signalling at the H452Y polymorphic form of the 5-HT2A receptor |
| Q33881804 | Behavioral Effects of Systemic, Infralimbic and Prelimbic Injections of a Serotonin 5-HT2A Antagonist in Carioca High- and Low-Conditioned Freezing Rats |
| Q37622283 | Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function. |
| Q41233440 | Characterization of the discriminative stimulus effects of lorcaserin in rats |
| Q42416010 | Commentary: Chronic SSRI stimulation of astrocytic 5-HT2B receptors change multiple gene expressions/editings and metabolism of glutamate, glucose and glycogen: a potential paradigm shift |
| Q53774324 | Control of sensory neuron excitability by serotonin involves 5HT2C receptors and Ca(2+)-activated chloride channels. |
| Q43486185 | DOI-induced deficits in prepulse inhibition in Wistar rats are reversed by mGlu2/3 receptor stimulation |
| Q40070016 | Development of a bicistronic vector for multimodality imaging of estrogen receptor activity in a breast cancer model: preliminary application |
| Q30492804 | Different serotonin receptor agonists have distinct effects on sound-evoked responses in inferior colliculus |
| Q43043558 | Discriminative stimulus effects of serotonin agonists, neutral antagonists, and inverse agonists in pigeons: perspectives on intrinsic efficacy measurements in vivo |
| Q35573424 | Drug discovery targeting human 5-HT(2C) receptors: residues S3.36 and Y7.43 impact ligand-binding pocket structure via hydrogen bond formation |
| Q37015833 | Effect of (-)-trans-PAT, a novel 5-HT2C receptor agonist, on intake of palatable food in mice |
| Q47783144 | Effects of a Serotonin 2C Agonist and a 2A Antagonist on Actigraphy-Based Sleep Parameters Disrupted by Methamphetamine Self-Administration in Rhesus Monkeys |
| Q34302242 | Effects of intracerebroventricular injections of 5-HT on systemic vascular resistances of conscious rats |
| Q37737291 | Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression |
| Q47645341 | Evaluating the dose-dependent mechanism of action of trazodone by estimation of occupancies for different brain neurotransmitter targets |
| Q34183122 | Evaluation of [(11)C]metergoline as a PET radiotracer for 5HTR in nonhuman primates. |
| Q34135689 | Evidence for noncompetitive modulation of substrate‐induced serotonin release |
| Q34660952 | Evidence for the participation of peripheral 5-HT2A, 5-HT2B, and 5-HT2C receptors in formalin-induced secondary mechanical allodynia and hyperalgesia |
| Q38661128 | Functional activation of Gαq coupled to 5-HT2A receptor and M1 muscarinic acetylcholine receptor in postmortem human cortical membranes |
| Q38109148 | Functional topography of serotonergic systems supports the Deakin/Graeff hypothesis of anxiety and affective disorders |
| Q46151811 | Genetic deletion of MAO-A promotes serotonin-dependent ventricular hypertrophy by pressure overload |
| Q24643885 | Guinea pig hippocampal 5-HT(1E) receptors: a tool for selective drug development |
| Q34438870 | Hallucinogen-like effects of 2-([2-(4-cyano-2,5-dimethoxyphenyl) ethylamino]methyl)phenol (25CN-NBOH), a novel N-benzylphenethylamine with 100-fold selectivity for 5-HT₂A receptors, in mice |
| Q37315499 | Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines |
| Q24595389 | Head‐twitch response in rodents induced by the hallucinogen 2,5‐dimethoxy‐4‐iodoamphetamine: a comprehensive history, a re‐evaluation of mechanisms, and its utility as a model |
| Q44278308 | Identification of 5‐HT2C mediated mechanisms involved in urethral sphincter reflexes in a guinea‐pig model of urethral function |
| Q46069455 | Identification of structural determinants of ligand selectivity in 5-HT2 receptor subtypes on the basis of protein–ligand interactions |
| Q87345890 | Insights into the influence of 5-HT2c aminoacidic variants with the inhibitory action of serotonin inverse agonists and antagonists |
| Q34359895 | Interaction of 5-HT2A and 5-HT2C Receptors in R(−)-2,5-Dimethoxy-4-iodoamphetamine-Elicited Head Twitch Behavior in Mice |
| Q34792786 | Investigation of the role of 5-HT2 receptor subtypes in the control of the bladder and the urethra in the anaesthetized female rat. |
| Q34430446 | Locomotion after spinal cord injury depends on constitutive activity in serotonin receptors |
| Q37679880 | Mechanism of action of trazodone: a multifunctional drug |
| Q28307141 | Mefloquine and psychotomimetics share neurotransmitter receptor and transporter interactions in vitro |
| Q39752554 | Molecular Dynamics Simulations and Docking Studies on 3D Models of the Heterodimeric and Homodimeric 5-Ht 2A Receptor Subtype |
| Q43274940 | Molecular modeling and docking studies of human 5-hydroxytryptamine 2A (5-HT2A) receptor for the identification of hotspots for ligand binding |
| Q34686451 | Motoneuron excitability and muscle spasms are regulated by 5-HT2B and 5-HT2C receptor activity |
| Q46899031 | Multiple conformations of 5-HT2A and 5-HT 2C receptors in rat brain: an autoradiographic study with [125I](±)DOI. |
| Q38101499 | Multiple controls exerted by 5-HT2C receptors upon basal ganglia function: from physiology to pathophysiology |
| Q35198061 | Native serotonin 5-HT2C receptors are expressed as homodimers on the apical surface of choroid plexus epithelial cells |
| Q35535506 | Neuroreceptor activation by vibration-assisted tunneling |
| Q48351742 | Novel Bivalent 5-HT2A Receptor Antagonists Exhibit High Affinity and Potency in Vitro and Efficacy in Vivo. |
| Q38648544 | Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014). |
| Q38531787 | Optimising PET approaches to measuring 5-HT release in human brain |
| Q46148909 | Platelet derived serotonin drives the activation of rat cardiac fibroblasts by 5-HT2A receptors |
| Q35160555 | Polysynaptic excitatory postsynaptic potentials that trigger spasms after spinal cord injury in rats are inhibited by 5-HT1B and 5-HT1F receptors |
| Q36936203 | Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays |
| Q30500846 | Recovery of motoneuron and locomotor function after spinal cord injury depends on constitutive activity in 5-HT2C receptors |
| Q35792549 | Regulation of 5-HT2A/C receptors and DOI-induced behaviors by protein kinase Cgamma |
| Q45908028 | Reversal of sibutramine-induced anorexia with a selective 5-HT(2C) receptor antagonist. |
| Q34660702 | Role of peripheral and spinal 5-HT2B receptors in formalin-induced nociception |
| Q54440509 | Role of serotonin 5-HT2A receptors in the development of cardiac hypertrophy in response to aortic constriction in mice |
| Q45050622 | Role of spinal 5-HT2 receptor subtypes in quipazine-induced hindlimb movements after a low-thoracic spinal cord transection |
| Q21262960 | SB 206553, a putative 5-HT2C inverse agonist, attenuates methamphetamine-seeking in rats |
| Q35046675 | Selective serotonin 5-HT(2C) receptor activation suppresses the reinforcing efficacy of cocaine and sucrose but differentially affects the incentive-salience value of cocaine- vs. sucrose-associated cues |
| Q47910593 | Serotonin (5-HT)2A/2C receptor agonist (2,5-dimethoxy-4-idophenyl)-2-aminopropane hydrochloride (DOI) improves voiding efficiency in the diabetic rat. |
| Q49026083 | Serotonin 2B receptor slows disease progression and prevents degeneration of spinal cord mononuclear phagocytes in amyotrophic lateral sclerosis |
| Q27015917 | Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder |
| Q91826240 | Serotonin activates glycolysis and mitochondria biogenesis in human breast cancer cells through activation of the Jak1/STAT3/ERK1/2 and adenylate cyclase/PKA, respectively |
| Q36680671 | Serotonin hyperinnervation and upregulated 5-HT2A receptor expression and motor-stimulating function in nigrostriatal dopamine-deficient Pitx3 mutant mice |
| Q39601650 | Serotonin receptor 5-HT2B mediates serotonin-induced mechanical hyperalgesia. |
| Q50624981 | Serotonin-2A receptor regulation of panic-like behavior in the rat dorsal periaqueductal gray matter: the role of GABA. |
| Q48125393 | Serotonin-2C receptors in the basolateral nucleus of the amygdala mediate the anxiogenic effect of acute imipramine and fluoxetine administration |
| Q91283766 | Serotonin-induced hyperactivity in SSRI-resistant major depressive disorder patient-derived neurons |
| Q36798864 | Serotonin2C Receptors and the Motor Control of Oral Activity |
| Q28547013 | Similarities between the Binding Sites of SB-206553 at Serotonin Type 2 and Alpha7 Acetylcholine Nicotinic Receptors: Rationale for Its Polypharmacological Profile |
| Q28288908 | Substituted methcathinones differ in transporter and receptor interactions |
| Q37125668 | Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response model |
| Q34257977 | Synthesis and SAR study of 4-arylpiperidines and 4-aryl-1,2,3,6-tetrahydropyridines as 5-HT2C agonists |
| Q58104764 | The 5-HT Receptor (5-HTR) Regulates Impulsive Action and Cocaine Cue Reactivity in Male Sprague-Dawley Rats |
| Q30486707 | The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors |
| Q38847601 | The Discriminative Stimulus Properties of Drugs Used to Treat Depression and Anxiety |
| Q24645656 | The behavioral pharmacology of hallucinogens |
| Q42436356 | The enhanced oral response to the 5-HT2 agonist Ro 60-0175 in parkinsonian rats involves the entopeduncular nucleus: electrophysiological correlates. |
| Q46703278 | The role of 5-HT2A and 5-HT2C receptors in the signal attenuation rat model of obsessive-compulsive disorder |
| Q34427453 | The role of 5-HT2A, 5-HT 2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens N,N-dimethyltryptamine and N,N-diisopropyltryptamine in rats and mice. |
| Q24620468 | The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen |
| Q41850897 | Trazodone regulates neurotrophic/growth factors, mitogen-activated protein kinases and lactate release in human primary astrocytes |
| Q37960634 | Trazodone: properties and utility in multiple disorders |
Search more.